Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Galena Biopharma, Inc.
Sponsor:
Information provided by (Responsible Party):
Galena Biopharma, Inc.
ClinicalTrials.gov Identifier:
NCT01479244
First received: November 20, 2011
Last updated: November 19, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2024
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)